Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Chengdu Easton Biopharmaceuticals Co Ltd banner

Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 64.39 CNY -3.19% Market Closed
Market Cap: ¥11.4B
Write Note Create Alert Ask AI

Intrinsic Value

The intrinsic value of one Chengdu Easton Biopharmaceuticals Co Ltd stock under the Base Case scenario is 39.45 CNY. Compared to the current market price of 64.39 CNY, Chengdu Easton Biopharmaceuticals Co Ltd is Overvalued by 39%.

Valuation Methods:
DCF Value
¥50.35
Relative Value
¥28.56
DCF Value
¥50.35
Relative Value
¥28.56
Intrinsic Value
39.45 CNY
Overvaluation 39%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Chengdu Easton Biopharmaceuticals Co Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about Chengdu Easton Biopharmaceuticals Co Ltd?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Chengdu Easton Biopharmaceuticals Co Ltd valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Chengdu Easton Biopharmaceuticals Co Ltd.

Explain Valuation
Compare Chengdu Easton Biopharmaceuticals Co Ltd to

Fundamental Analysis

Financials
Efficiency

Earnings Waterfall
Chengdu Easton Biopharmaceuticals Co Ltd

Wall St
Price Targets

Dividends

Shareholder Yield

Competitive Landscape

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is the Intrinsic Value of one Chengdu Easton Biopharmaceuticals Co Ltd stock?

The intrinsic value of one Chengdu Easton Biopharmaceuticals Co Ltd stock under the Base Case scenario is 39.45 CNY.

Is Chengdu Easton Biopharmaceuticals Co Ltd stock undervalued or overvalued?

Compared to the current market price of 64.39 CNY, Chengdu Easton Biopharmaceuticals Co Ltd is Overvalued by 39%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 319,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.